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Background: Direct stenting (DS) may potentially reduce vessel trauma, minimize “geographical miss”, prevent distal embolization and save time/
money during PCI. However, DS is currently performed in < 50%. Among the main reasons to pre-dilate, vessel anatomy (tortuosity and amount of 
calcification) plays a central role in the operator’s decision. Recently developed, the Acrobat SOAW (Stent-On-A-Wire) coronary system combines a 
very-thin (81 μ) balloon-expandable, Cro-Co (L605) stent mounted on a delivery system with a 0.012” integrated guidewire tip (distance from the tip 
of the wire to the stent is 22mm). We sought to determine the efficacy profile of this novel device.
Methods: SVELTE trial is a multicenter, international (Brazil, Netherlands and Colombia), prospective, non-randomized, single-arm study of the 
Acrobat SOAW for the treatment of de novo coronary lesions no longer than 18mm and located in native vessels of 2.5 to 3.5mm. DS was highly 
recommended and post-dilatation was at operator’s discretion. Patients were oriented to stay on dual anti-platelet regimen for at least 1 month. 
Main exclusion criteria were PCI in the setting of acute ST-elevation MI and bifurcation lesions. All patients were scheduled to undergo angiographic 
follow-up at 6 months. The primary endpoint of the study was the survival-free of combined MACE (cardiac death, myocardium infarction and target-
lesion revascularization) at 30 days. Secondary endpoints included 6-month in-stent late lumen loss and binary restenosis as well as combined 
MACE rate.
Results: A total of 46 patients were enrolled with mean age of 63 years old, 76.6% of male and 21.3% of diabetics. Mean RVD and lesion length 
were 3.03mm and 12.67mm, respectively. The Acrobat stent was deployed in 100% of the cases (89.6% of DS) achieving a procedure success rate 
of 97.8%. Up to 30 days there were no deaths, Q-Wave MIs or urgent TLR. Six-month invasive follow-up is ongoing and complete QCA assessment will 
be available at the meeting.
Conclusions: The Acrobat SOAW may potentially facilitate PCI by reducing time/cost and minimizing peri-procedural complications. The present 
trial represents the first-in-man assessment of this innovative concept.
